Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases

ABSTRACT

A method is used for treating bone metastasis diseases in subjects. The method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment. The treatment includes the administration of at least one pan αv integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan αv integrin inhibitor based on the specific protein levels in one or more body fluids of the subject.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 16/518,174, filed on Jul. 22, 2019, which was a continuation of U.S. application Ser. No. 15/511,959, filed on Mar. 16, 2017, which was the National Stage entry under § 371 of International Application No. PCT/EP2015/001701, filed on Aug. 18, 2015, and which claims the benefit of U.S. Provisional Application No. 62/051,525, filed on Sep. 17, 2014. The content of each of these applications is hereby incorporated by reference in its entirety.

REFERENCE TO A SEQUENCE LISTING

The present application is accompanied by an ASCII text file as a computer readable form containing the sequence listing entitled, “000784USCONT02_SL_ST25.txt”, created on May 20, 2022, with a file size of 98,146 bytes, the content of which is hereby incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION Field of the Invention

The instant invention provides for a new method of treating bone metastasis diseases in subjects, wherein said method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment, wherein said treatment comprises the administration of at least one pan αv integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan αv integrin inhibitor based on said specific protein levels in one or more body fluids of the subject.

More specifically, the instant invention provides for a new method of treating of treating bone metastasis diseases, preferably bone metastasis disease is derived from prostate cancer, breast cancer and/or cancer in subjects with at least one pan αv integrin inhibitor, preferably including the pan αv integrin inhibitor abituzumab or Intetumumab, wherein said subjects show certain specific protein levels in one or more body fluids prior to or during treatment.

Description of Related Art

Bone metastases, or metastatic bone disease, is a class of cancer metastases that results from primary tumor invasion to bone. Bone is one of the most common locations for metastasis. [Coleman RE (October 2006). “Clinical features of metastatic bone disease and risk of skeletal morbidity”. Clin. Cancer Res. 12 (20 Pt 2): 6243s-9s.] While any type of cancer is capable of forming metastatic tumors within bone, the microenvironment of the marrow tends to favor particular types of cancer, including prostate, breast, and lung cancers. [Guise T (October 2010). “Examining the metastatic niche: targeting the microenvironment”. Semin. Oncol. 37 (Suppl 2): S2-14.] Particularly in prostate cancer, bone metastases tend to be the only site of metastasis. [Jimenez-Andrade J M, Mantyh W G, Bloom A P, Ferng A S, Geffre C P, Mantyh P W (June 2010). “Bone cancer pain”. Annals of the New York Academy of Sciences 1198: 173-81.]

Lung cancer, also known as carcinoma of the lung or pulmonary carcinoma, is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. If left untreated, this growth can spread beyond the lung by process of metastasis into nearby tissue or other parts of the body, including the liver, brain and bone. Most cancers that start in the lung, known as primary lung cancers, are carcinomas that derive from epithelial cells. The main primary types are small-cell lung carcinoma (SCLC), and non-small-cell lung carcinoma (NSCLC). Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). As a class, NSCLCs and metastases thereof are relatively insensitive to chemotherapy, compared to small cell carcinoma. A wide variety of chemotherapies are used in metastatic NSCLC, unfortunately with little effect to date. Small-cell carcinoma or small-cell lung cancer (SCLC) is a type of highly malignant cancer that most commonly arises within the lung, although it can occasionally arise in other body sites, such as the cervix, prostate, and gastrointesinal tract. SCLC usually metastasizes widely very early on in the natural history of the tumor. Also in this case, the metastasis affects predominantely the bone, liver and brain.

Breast cancer develops from breast tissue. It most commonly develops in cells from the lining of milk ducts and the lobules that supply the ducts with milk. Cancers developing from the ducts are known as ductal carcinomas, while those developing from lobules are known as lobular carcinomas. In addition, there are more than 18 other sub-types of breast cancer. The diagnosis of breast cancer is regularily confirmed by taking a biopsy of the concerning lump. Once the diagnosis is made, further tests are done to determine if the cancer has spread beyond the breast and which treatments it may respond to. If the cancer has spread beyond the breast, the breast cancer presents as metastatic disease. The symptoms caused by metastatic breast cancer will depend on the location of metastasis. Common sites of metastasis include bone, liver, lung and brain.

The metastatic process is a multistep event and represents the most dreadful aspect of cancer. At the moment of diagnosis, cancers are frequently far advanced in their natural history, and the presence of metastases is a common event. In fact, approximately 30% of patients have detectable metastases at the moment of clinical diagnosis and a further 30% of patients have occult metastases. Metastases can be disseminated and they can infest different organs at the same time, or localize to a specific organ. In the case of localized disease, surgery is the treatment of choice; however recurrence and prognosis depend on many criteria such as: resectability, patient's clinical situation, and number of metastases. After resection, recurrence is common, suggesting that micrometastatic foci are present at the moment of diagnosis. Systemic chemotherapy is an ideal setting but only few patients are cured by it, and in the majority systemic chemotherapy fails. Many physiological barriers and pharmacokinetic parameters contribute to decrease its efficacy.

Liver, lungs and lymph nodes are filtration organs and therefore inclined to metastasization. The poor chemosensitivity of metastases, peculiarly those of colorectal origin has forced many researchers to use methods for increasing the time and the concentration of drugs. The need for decreasing or limiting the side effects for this important and delicate organ led to the development of the technique of liver isolation for perfusion of antineoplastic agents. (K. R. Aigner, Isolated liver perfusion. In: Morris D L, McArdle C S, Onik G M, eds. Hepatic Metastases. Oxford: Butterworth Heinemann, 1996. 101-107). Since 1981, modifications and technical improvements have been continuously introduced. Liver metastases may be of different origin and their chemosensitivity may vary according to the histological type and their response in presence of heat.

There still exists a growing need in the art in order to develop new therapeutic strategies for treating cancer, especially metastases, systemically.

SUMMARY OF THE INVENTION

The object of the present invention therefore was to develop such a new strategy. It should be applicable to systemic treatment, and it should lower the dose and/or increase the efficiency of the cancer therapeutical agents to be applied. A further object was to normalize tumor vasculature to increase delivery of systemic therapeutics of tumor, i.e. to reset the tumor vasculature to the functionality of the vasculature of non-tumor tissue.

Thus, it is a preferred objective of the instant invention to provide a more effective, better tolerated treatment for humans, especially human cancer patients suffering from bone metastases, preferably bone metastases independent from their origin, thus preferably leading to enhanced overall survival (OS), progression-free survival (PFS), quality of life (QOL) and/or increased median survival.

Prostate cancer is the most commonly occurring cancer aside skin cancer in the US, and is the second most common cause of male cancer deaths. Prostate cancer is classified in four stages: Stage I prostate cancer is found in the prostate only and cannot be felt during a digital rectal exam nor is it visible by imaging. In stage II prostate cancer, the tumor has grown inside the prostate but has not extended beyond it, whereas in stage III, the cancer has spread outside the prostate, but to a minimal extent only. Often, prostate cancer in stage III will have spread only to nearby tissues, such as the seminal vesicles. Finally, in stage IV, the cancer has spread outside the prostate to other tissues, such as the lymph nodes, bones, liver, and/or lungs or brain.

The spectrum of prostate cancers that are progressing despite castrate levels of testosterone includes tumors that have shown varying degrees and durations of response to primary hormone treatment, and clinical manifestations that range from a rising prostate-specific antigen (PSA) alone, a rising PSA with osseous and/or soft-tissue spread, or a predominantly visceral disease pattern.

Currently approved treatment of prostrate cancer includes surgical castration, chemical castration, or a combination of surgical and chemical castration. Removal of the testes, the primary testosterone producing organ, reduces the levels of circulating androgens, to less than 5% of normal levels. This reduction in androgen levels inhibits prostate tumor growth. Although the anti-tumor effects of surgical castration are direct, the anti-tumor effects can be temporary. Surgical castration often leads to clonal selection of androgen-independent prostate tumor cells. This results in re-growth of the prostate tumor in a form that proliferates without testosterone or DHT Stimulation. Chemical castration (also called medical castration) is often substituted for surgical castration, as an initial treatment. Despite its high prevalence, treatment options for men having prostate cancer remain relatively limited and typically depend on the stage of the cancer.

Treatment options include surgical treatments such as radical prostatectomy, in which the prostate is completely removed and radiation, applied through an external beam that directs the dose to the prostate from outside the body or via low-dose radioactive seeds that are implanted within the prostate to kill cancer cells locally. Anti-androgen hormone therapy also is used in the treatment of prostate cancer, either alone or in conjunction with surgery or radiation. Hormone therapy typically aims at blocking the pituitary from producing hormones that stimulate testosterone production by use of castration or administration of hormone analogs and requires that patients have injections of these hormone analogs for protracted periods. Finally, chemotherapeutic approaches have been used to treat advanced prostate cancer, usually as a last resort when other approaches have failed. Since a couple of years, the combination of docetaxel and prednisone was established as the new standard of care for patients who have progressed on androgen deprivation.

None of the treatments described above are curative and prostate cancer being androgen dependent at first, often will progress despite surgical and hormonal-based therapies, and become resistant over time, leading to a cancer type which is called “hormone refractory cancer” or “castration resistant cancer” (CRPC).

Clinical disease manifestations of CRPC are commonly related to bone metastases and may include pain, pathologic fractures, and spinal cord compression, with local recurrences that may be associated with pelvic discomfort, renal dysfunction due to ureteral compression, bladder outlet obstruction, and sexual dysfunction. Further, while bone cancer is the predominant result of CRPC, patients may develop soft-tissue metastases (lymph node(s)) and visceral metastasis in liver, lung, brain, and other organs. Patients with CRPC are minimally responsive to chemotherapy and the majority of patients die due to progressive prostate cancer within 20 months of initiating treatment. Bisphosphonates are commonly used in patients with castrate-resistant prostate cancer who have bone metastases.

It has been shown that prostate tumors remain dormant and clinically undetectable until they begin to secrete angiogenic factors and down-regulate the expression of angiogenic inhibitors. In general, it can be stated that angiogenesis is critical to the genesis of prostate tumors. Therefore, it was not completely surprising that anti-angiogenic agents may inhibit prostate cancer cell growth.

In prostate cancer, tumor cells express an abnormal integrin repertoire and are surrounded by a markedly aberrant extracellular matrix (ECM). These changes have profound consequences, given the ability of each integrin to regulate specific cell functions. Expression of β3 and β1 subunits activates specific signaling pathways and support distinct cancer cell functions. β3 is uniquely required in cancer cells for increasing cdc2 levels as well as cdc2 kinase activity. These effects are specific for β3 and are not observed for β6. Up-regulation of β3 and β6 integrin variants has been described. Zheng et al. (Cancer Research 1999; 59, 1655-1664) used human prostate cancer cells isolated from sixteen surgical specimens, to show that these cells express αvβ3, whereas normal prostate epithelial cells do not. Similarly, αvβ6 was found to be expressed in adenocarcinoma (Azare et al.; Molecular and Cellular Biology 2007; 27, 4444).

The use of integrin inhibitors is likely to affect both cancer cell survival and angiogenesis since integrins are expressed by tumor cells as well as by endothelial cells. Although it is hard to discriminate between an effect on tumor growth and an effect on angiogenesis, a maximal response of these inhibitors can be predicted when the targeted integrin is expressed by both tumor and endothelial cells.

Bone is the most frequent metastatic site for prostate cancer. Bisanz et al. (Molecular Therapy 2005; 12, 634-643) illustrate a positive role for alpha-v integrins on prostate tumor survival in the bone. Analysis of human prostate cancer bone xenografts shows that intratumoral administration of liposome encapsulated human alpha-v siRNAs significantly inhibits the growth of PC3 tumors in bone and increases apoptosis of prostate tumor cells. Further studies (McCabe et al., Oncogene 2007; 26, 6238-6243) demonstrate that αvβ3 integrin activation on tumor cells is essential for the recognition of key bone specific matrix proteins. These data suggest that the αvβ3 integrin modulates prostate cancer growth in distant metastasis.

Since integrins mediate the interactions between tumor cells and bone microenvironment and facilitate growth in bone, a potential application of the use of integrin inhibitors is to prevent prostate cancer bone lesions. These lesions are osteoblastic and/or osteolytic and are frequently detected in prostate cancer patients (over 80% of prostate cancer patients have established bone metastasis at autopsy).

A recent study has shown that the αvβ3 integrin promotes bone gain mediated by prostate cancer cells that metastasize to the bone and point to αvβ3 as a potential therapeutic target to block prostate cancer osteoblastic lesions. Immunohistochemical analysis has demonstrated the presence of αv integrin in a large proportion of human prostate cancer tissues samples. These and other results suggest that anti-integrin agents may have both direct and indirect antitumor activity. But there are only few clinical trials reporting that peptide or non-peptide integrin inhibitors are effective agents in prostate cancer therapy.

Therefore, there is a need to provide a method of treatment of bone metastases, preferably bone metastases of breast cancer, lung cancer and/or prostate cancer. Moreover, there is a especially high need to provide a method for the treatment of prostate cancer bone metatases, especially castration-resistant prostate cancer bone metastases.

Therefore, there is a also a need to provide a method of treatment of bone metastases from metastatic androgen independent prostate cancer (mAIPCa) and/or bone metastases from metastatic androgen dependent prostate cancer (mADPCa).

According to an aspect of the invention there is provided a method for identifying bone metastasis in a subject, preferably a human subject, that is susceptible to treatment with at least one pan αv integrin inhibitor, preferably Abituzumab, comprising determining said certain proteins levels in one or more body fluids, whereby a high level of one or more proteins selected from a first group of said specific proteins and/or a low level of one or more proteins from a second group of said specific proteins indicates the tumor is susceptible to said treatment.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 displays rPFS of patients with high and low expressions of MAPK11 for EMD 525797-treated patients and placebo-treated patients.

FIG. 2 displays rPFS of EMD 525797-treated patients and placebo-treated patients for high and low expressions of MAPK11.

FIG. 3 displays rPFS of patients with high and low expressions of STX1A for EMD 525797-treated patients and placebo-treated patients.

FIG. 4 displays rPFS of EMD 525797-treated patients and placebo-treated patients for high and low expressions of STX1A.

FIG. 5 displays rPFS of patients with high and low expressions of MAP2K2 for EMD 525797-treated patients and placebo-treated patients.

FIG. 6 displays rPFS of EMD 525797-treated patients and placebo-treated patients for high and low expressions of MAP2K2.

FIG. 7 displays rPFS of patients with high and low expressions of TNFRSF17 for EMD 525797-treated patients and placebo-treated patients.

FIG. 8 displays rPFS of EMD 525797-treated patients and placebo-treated patients for high and low expressions of TNFRSF17.

FIG. 9 displays rPFS of patients with high and low expressions of RGMB for EMD 525797-treated patients and placebo-treated patients.

FIG. 10 displays rPFS of EMD 525797-treated patients and placebo-treated patients for high and low expressions of RGMB.

FIG. 11 displays rPFS of patients with high and low expressions of LEPR for EMD 525797-treated patients and placebo-treated patients.

FIG. 12 displays rPFS of EMD 525797-treated patients and placebo-treated patients for high and low expressions of LEPR.

FIG. 13 displays rPFS of patients with high and low expressions of IL1B for EMD 525797-treated patients and placebo-treated patients.

FIG. 14 displays rPFS of EMD 525797-treated patients and placebo-treated patients for high and low expressions of IL1B.

FIG. 15 displays rPFS of patients with high and low expressions of ICAM3 for EMD 525797-treated patients and placebo-treated patients.

FIG. 16 displays rPFS of EMD 525797-treated patients and placebo-treated patients for high and low expressions of ICAM3.

FIG. 17 displays rPFS of patients with high and low expressions of F5 for EMD 525797-treated patients and placebo-treated patients.

FIG. 18 displays rPFS of EMD 525797-treated patients and placebo-treated patients for high and low expressions of F5.

FIG. 19 displays rPFS of patients with high and low expressions of ANG for EMD 525797-treated patients and placebo-treated patients.

FIG. 20 displays rPFS of EMD 525797-treated patients and placebo-treated patients for high and low expressions of ANG.

FIG. 21 displays rPFS of patients with high and low expressions of PIGR for EMD 525797-treated patients and placebo-treated patients.

FIG. 22 displays rPFS of EMD 525797-treated patients and placebo-treated patients for high and low expressions of PIGR.

FIG. 23 displays rPFS of patients with high and low expressions of TEK for EMD 525797-treated patients and placebo-treated patients.

FIG. 24 displays rPFS of EMD 525797-treated patients and placebo-treated patients for high and low expressions of TEK.

DETAILED DESCRIPTION OF THE INVENTION

Body fluids are preferably the liquids originating from inside the bodies of living subjects, preferably living human subjects. They include fluids that are excreted or secreted from the body as well as body water that normally is not excreted or secreted.

The body fluids can preferably specified by type, such as intracellular fluids, extracellular fluids, intravascular fluids (e.g. whole blood, blood and blood plasma), interstitial fluids, lymphatic fluids (sometimes regarded as a subtype of interstitial fluids), and transcellular fluids.

Preferred body fluids are selected from the group consisting of whole blood (preferably also referred to as “blood”), blood serum (preferably also referred to as “serum”), blood plasma (preferably also referred to as “plasma”), exudate, lymph, mucus, peritoneal fluid, saliva, sputum, tears and urine. Especially preferred body fluids are selected from the group consisting of Preferred body fluids are selected from the group consisting of whole blood (preferably also referred to as “blood”), blood serum (preferably also referred to as “serum”), and blood plasma (preferably also referred to as “plasma”). Especially preferred is blood plasma (preferably also referred to as “plasma”). Alternatively preferred is blood serum (preferably also referred to as “serum”), and whole blood (preferably also referred to as “blood”).

The threshold for categorization of patients into “low level” or “high level” for each of said specific proteins is preferably determined by listing of all available levels for that respective specific protein in the respective body fluid, then determining the median from this listing of said specific protein level values in said body fluid, and taking this median value as the threshold.

This threshold is preferably also referred to herein as median threshold. Preferably, said threshold or median threshold is determined in the population of subjects suffering from the respective bone metastasis disease as described herein. More preferably, said threshold or median threshold for the respective specific protein is determined from the body fluid of a plurality of subjects being part of a diseased subject population suffering from the respective bone metastasis disease.

For example, for determining said median threshold for one or more said specific proteins, body fluid samples (here: blood samples) are taken from 150 human subjects suffering from metastatic castrate-resistant prostate cancer (mCRPC) in order to obtain about 500 μL offer a preferred body fluid (here: blood plasma). The levels of the contained specific proteins of interest, e.g. STX1A are determined using an aptamer based protein detection system, e.g. the SomaLogic Proteomic Affinity Assay Method described in detail in the Experimental Section, whereby results for each protein of interest are represented by relative fluorescence readouts reported by the detection system. In an optional next step, the obtained raw data set can be simplified by removing the data of proteins not of interest, e.g. proteins that are known to be derived or affected by inadequate sample handling during plasma protein, such as platelet activation or cell lysis which may occur during the plasma preparation process. The thus obtained data set is then preferably subjected to steps such as data normalization procedures in order to obtain robust signals of the proteins of interest and estimates of the median protein levels across the study population of patients. Preferably, this data analysis process includes a cut-of optimisation. This procedure thus provides a median threshold of one or more specific proteins of interest, e.g. the median threshold for the protein STX1A. Taking this obtained median threshold, both said 150 human subjects suffering from metastatic castrate-resistant prostate cancer (mCRPC), as well as future human subjects suffering from mCRPC, can then be readily characterised as having a high level or a low level, respectively, of one or more specific proteins of interest, e.g. STX1A, with the predicted specific impact on the clinical outcome of the treatment with at least one pan αv integrin inhibitor, optionally in combination with one or more chemotherapeutic agents.

Preferably, the body fluid sampling and/or the evaluation of the median value for the respective specific protein is performed prior to treatment of the respective bone metastasis disease with said at least one pan αv integrin inhibitor. Preferably, patients are classified as “high level” if their respective specific protein level in said body fluid is higher than the median threshold. Accordingly, patients are preferably classified as “low level” if their respective specific protein level in said body fluid is lower than or equal to said median threshold.

More preferably, the threshold for categorization of patients into “low level” or “high level” for each of said specific proteins is preferably determined by listing of all available levels for that respective specific protein in the blood plasma, then determining the median from this listing of said specific protein level values in said blood plasma, and taking this median value as the threshold. This threshold is preferably also referred to herein as median threshold. Preferably, the blood plasma sampling and/or the evaluation of the median value for the respective specific protein is performed prior to treatment of the respective bone metastasis disease with said at least one pan αv integrin inhibitor. Preferably, patients are classified as “high level” if their respective specific protein level in said blood plasma is higher than the median threshold. Accordingly, patients are preferably classified as “low level” if their respective specific protein level in said blood plasma is lower than or equal to said median threshold. Preferably, the respective bone metastasis disease in this regard is metastatic prostate cancer, more preferably metastatic castration-resistant prostate cancer (mCRPC). Preferably, the at least one pan αv integrin inhibitor comprises Abituzumab or Intetumumab). More preferably, the at least one pan αv integrin inhibitor is Abituzumab or Intetumumab. Especially preferred, the at least one pan αv integrin inhibitor is Abituzumab.

More preferably, the threshold for categorization of patients into “low level” or “high level” for each of said specific proteins is preferably determined by listing of all available levels for that respective specific protein in the blood plasma, then determining the median from this listing of said specific protein level values in said blood plasma, and taking this median value as the threshold. This threshold is preferably also referred to herein as median threshold. Preferably, the blood plasma sampling and/or the evaluation of the median value for the respective specific protein is performed prior to treatment of the respective bone metastasis disease with said at least one pan αv integrin inhibitor. Preferably, patients are classified as “high level” if their respective specific protein level in said blood plasma is higher than the median threshold. Accordingly, patients are preferably classified as “low level” if their respective specific protein level in said blood plasma is lower than or equal to said median threshold. Preferably, the respective bone metastasis disease in this regard is metastatic prostate cancer, more preferably metastatic castration-resistant prostate cancer (mCRPC). Preferably, the at least one pan αv integrin inhibitor comprises Abituzumab or Intetumumab). More preferably, the at least one pan αv integrin inhibitor is Abituzumab or Intetumumab. Especially preferred, the at least one pan αv integrin inhibitor is Abituzumab.

Methods to determine said threshold level and especially said median threshold level are known in the art. Examples of suitable technologies include, but are not limited to the SomaLogic technology, preferably the SomaLogic Proteomic Affinity Assay technology, SomaLogic SOMAscan™/V3/Version 10.5.1.1, ELISA (Enzyme-Linked Immuno-Sorbent Assays) technologies and variants thereof, including the RIA (Radio Immuno Assay) technology as high sensitivity variant, the 2D SDS-Polyacryamid electrophorese (SDS-PAGE) Mass Spectrometry technology, and Proximity Ligation Assay (PLA) technologies.

More specifically, the threshold for classification of patients into the ‘high’ and ‘low’ groups on the basis of plasma levels of the mentioned proteins is preferably the median plasma level across the patient population. The threshold may show a slight, but irrelevant dependency from the actual technology employed.

Preferably, protein plasma levels of samples that are to be classified are measured using the SomaLogic technology, preferably the SomaLogic Proteomic Affinity Assay technology (Somalogic, Inc., 2945 Wilderness PI, Boulder, Colo. 80301, USA, software package and version number as described herein) as described herein. The median plasma levels that are accordingly identified can be used as threshold for classification into ‘low’ and ‘high’ categories, preferably after the new SomaLogic patient profile is processed with data normalization steps, such as it has been performed in the analysis described herein. For example, the patient's pre-treatment proteomic profiles on 888 plasma protein levels—as it is prepared by the SomaLogic system-can advantageously be combined with existing pre-treatment data set for all samples, variance stabilzation as implemented in the vsn2 package which was applied. Finally, the normalized patient's pre-treatment level for the specific protein of interest (median thresholds for predicitivity for radiologic PFS-MAPK11: 9.46, STX1A: 9.06, MAP2K2: 11.9, TNFRSF17: 12.5, RGMB: 11.0, LEPR:11.2, IL1B:11.1, ICAM3:10.4, F5:15.7, ANG:12.5, PIGR:12.6, TEK:11.3; all median thresholds are given as protein level units on a log 2 scale as measured by Somalogic technology and after variance-stabilizing normalization of the data set) as received from the clinical study described herein (PERSEUS study). In case no prior data set is available, or the technology to measure the plasma protein levels is not the SomaLogic technology, the median population plasma level—as it comes from the new technology or the new patient population (that preferably comprises at least 120 patients for the respective indication) is preferably termined first, then classification can be readily done on the basis of the new population median.

Especially preferably, patients are classified as “high level” if their respective specific protein level in said blood plasma is at least 2% higher, more preferably at least 5% higher, even more preferably at least 10% higher and especially at least 25% higher than said median threshold for the respective specific protein.

Especially preferably, patients are classified as “low level” if their respective specific protein level in said blood plasma is at least 2% lower, more preferably at least 5% lower, even more preferably at least 10% lower and especially at least 25% lower than said median threshold for the respective specific protein.

Preferably, said specific proteins according to the invention comprise

a) one or more proteins, selected from the group consisting of

DCN (Somamer ID: SL004081; UniProt ID: P07585), F5 (Somamer ID: SL000622; UniProt ID: P12259), ICAM3 (Somamer ID: SL003178; UniProt ID: P32942), PIGR (Somamer ID: SL005797; UniProt ID: P01833), STK17B (Somamer ID: SL016566; UniProt ID: 094768), STX1A (Somamer ID: SL004304; UniProt ID: Q16623), and TEK (Somamer ID: SL003200; UniProt ID: Q02763),

and/or b) one or more proteins, selected from the group consisting of

ANG (Somamer ID: SL000003; UniProt ID: P03950), IL1B (Somamer ID: SL001795; UniProt ID: P01584), LEPR (Somamer ID: SL003184; UniProt ID: P48357), MAP2K2 (Somamer ID: SL010501; UniProt ID: P36507), MAPK11 (Somamer ID: SL007453; UniProt ID: Q15759), RGMB (Somamer ID: SL010468; UniProt ID: Q6NW40), and TNFRSF17 (Somamer ID: SL004672; UniProt ID: Q02223)

and/or preferably also proteins having at least 80%, more preferably at least 90%, even more preferably at least 95% and especially at least 99% sequence homology to said specific proteins.

More preferably, said specific proteins according to the invention comprise

a) one or more proteins, selected from the group consisting of

F5 (Somamer ID: SL000622; UniProt ID: P12259), ICAM3 (Somamer ID: SL003178; UniProt ID: P32942), PIGR (Somamer ID: SL005797; UniProt ID: P01833), STX1A (Somamer ID: SL004304; UniProt ID: Q16623), and TEK (Somamer ID: SL003200; UniProt ID: Q02763),

and/or b) one or more proteins, selected from the group consisting of

ANG (Somamer ID: SL000003; UniProt ID: P03950), IL1B (Somamer ID: SL001795; UniProt ID: P01584), LEPR (Somamer ID: SL003184; UniProt ID: P48357), MAP2K2 (Somamer ID: SL010501; UniProt ID: P36507), MAPK11 (Somamer ID: SL007453; UniProt ID: Q15759), RGMB (Somamer ID: SL010468; UniProt ID: Q6NW40), and TNFRSF17 (Somamer ID: SL004672; UniProt ID: Q02223)

and/or preferably also proteins having at least 80%, more preferably at least 90%, even more preferably at least 95% and especially at least 99% sequence homology to said specific proteins.

More preferably, a high level as defined herein for one or more specific proteins in the respective body fluid, preferably in the blood plasma, of the patient is advantageous with respect to the clinical outcome, if said high level of said one or more specific proteins in said body fluid comprises one or more of the proteins selected from the group consisting of

DCN (Somamer ID: SL004081; UniProt ID: P07585), F5 (Somamer ID: SL000622; UniProt ID: P12259), ICAM3 (Somamer ID: SL003178; UniProt ID: P32942), PIGR (Somamer ID: SL005797; UniProt ID: P01833), STK17B (Somamer ID: SL016566; UniProt ID: 094768), STX1A (Somamer ID: SL004304; UniProt ID: Q16623), and TEK (Somamer ID: SL003200; UniProt ID: Q02763),

even more preferably one or more of the proteins selected from the group consisting of

F5 (Somamer ID: SL000622; UniProt ID: P12259), ICAM3 (Somamer ID: SL003178; UniProt ID: P32942), PIGR (Somamer ID: SL005797; UniProt ID: P01833), STX1A (Somamer ID: SL004304; UniProt ID: Q16623), and TEK (Somamer ID: SL003200; UniProt ID: Q02763),

and/or preferably also proteins having at least 80%, more preferably at least 90%, even more preferably at least 95% and especially at least 99% sequence homology to said specific proteins.

More preferably, a low level as defined herein for one or more specific proteins in the respective body fluid, preferably in the blood plasma, of the patient is advantageous with respect to the clinical outcome of the treatment of the respective bone metastasis disease with the at least one pan αv integrin inhibitor, if said low level of said one or more specific proteins in said body fluid comprises one or more of the proteins selected from the group consisting of

ANG (Somamer ID: SL000003; UniProt ID: P03950), IL1B (Somamer ID: SL001795; UniProt ID: P01584), LEPR (Somamer ID: SL003184; UniProt ID: P48357), MAP2K2 (Somamer ID: SL010501; UniProt ID: P36507), MAPK11 (Somamer ID: SL007453; UniProt ID: Q15759), RGMB (Somamer ID: SL010468; UniProt ID: Q6NW40), and TNFRSF17 (Somamer ID: SL004672; UniProt ID: Q02223)

and/or preferably also proteins having at least 80%, more preferably at least 90%, even more preferably at least 95% and especially at least 99% sequence homology to said specific proteins.

Said specific proteins are preferably characterised by the following sequences and/or sequence IDs (Amino acid sequences of protein listed in Table 1 as identified by UniProt IDs in FASTA format):

ANG (SEQ ID NO: 12):  >sp|P03950|ANGI_HUMAN Angiogenin OS = Homo sapiens  GN = ANG PE = 1 SV = 1  MVMGLGVLLLVFVLGLGLTPPTLAQDNSRYTHFLTQHYDAKPQGRDDRYC  ESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSF QVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRRP  DCN (SEQ ID NO:13):  >sp|P07585|PGS2_HUMAN Decorin OS = Homo sapiens  GN = DCN PE = 1 SV = 1 MKATIILLLLAQVSWAGPFQQRGLFDFMLEDEASGIGPEVPDDRDFEPSL GPVCPFRCQCHLRVVQCSDLGLDKVPKDLPPDTTLLDLQNNKITEIKDGD FKNLKNLHALILVNNKISKVSPGAFTPLVKLERLYLSKNQLKELPEKMPK TLQELRAHENEITKVRKVTFNGLNQMIVIELGTNPLKSSGIENGAFQGMK KLSYIRIADTNITSIPQGLPPSLTELHLDGNKISRVDAASLKGLNNLAKL GLSFNSISAVDNGSLANTPHLRELHLDNNKLTRVPGGLAEHKYIQVVYLH NNNISVVGSSDFCPPGHNTKKASYSGVSLFSNPVQYWEIQPSTFRCVYVR SAIQLGNYK  F5 (SEQ ID NO: 14):  >sp|P12259|FA5_HUMAN Coagulation factor V  OS = Homo sapiens GN = F5 PE = 1 SV = 4  MFPGCPRLWVLVVLGTSWVGWGSQGTEAAQLRQFYVAAQGISWSYRPEPT NSSLNLSVTSFKKIVYREYEPYFKKEKPQSTISGLLGPTLYAEVGDIIKV HFKNKADKPLSIHPQGIRYSKLSEGASYLDHTFPAEKMDDAVAPGREYTY EWSISEDSGPTHDDPPCLTHIYYSHENLIEDFNSGLIGPLLICKKGTLTE GGTQKTFDKQIVLLFAVFDESKSWSQSSSLMYTVNGYVNGTMPDITVCAH DHISWHLLGMSSGPELFSIHFNGQVLEQNHHKVSAITLVSATSTTANMTV GPEGKWIISSLTPKHLQAGMQAYIDIKNCPKKTRNLKKITREQRRHMKRW EYFIAAEEVIWDYAPVIPANMDKKYRSQHLDNFSNQIGKHYKKVMYTQYE DESFTKHTVNPNMKEDGILGPIIRAQVRDTLKIVFKNMASRPYSIYPHGV TFSPYEDEVNSSFTSGRNNTMIRAVQPGETYTYKWNILEFDEPTENDAQC LTRPYYSDVDIMRDIASGLIGLLLICKSRSLDRRGIQRAADIEQQAVFAV FDENKSWYLEDNINKFCENPDEVKRDDPKFYESNIMSTINGYVPESITTL GFCFDDTVQWHFCSVGTQNEILTIHFTGHSFIYGKRHEDTLTLFPMRGES VTVTMDNVGTWMLTSMNSSPRSKKLRLKFRDVKCIPDDDEDSYEIFEPPE STVMATRKMHDRLEPEDEESDADYDYQNRLAAALGIRSFRNSSLNQEEEE FNLTALALENGTEFVSSNTDIIVGSNYSSPSNISKFTVNNLAEPQKAPSH QQATTAGSPLRHLIGKNSVLNSSTAEHSSPYSEDPIEDPLQPDVTGIRLL SLGAGEFKSQEHAKHKGPKVERDQAAKHRFSWMKLLAHKVGRHLSQDTGS PSGMRPWEDLPSQDTGSPSRMRPWKDPPSDLLLLKQSNSSKILVGRWHLA SEKGSYEIIQDTDEDTAVNNWLISPQNASRAWGESTPLANKPGKQSGHPK FPRVRHKSLQVRQDGGKSRLKKSQFLIKTRKKKKEKHTHHAPLSPRTFHP LRSEAYNTFSERRLKHSLVLHKSNETSLPTDLNQTLPSMDFGWIASLPDH NQNSSNDTGQASCPPGLYQTVPPEEHYQTFPIQDPDQMHSTSDPSHRSSS PELSEMLEYDRSHKSFPTDISQMSPSSEHEVWQTVISPDLSQVTLSPELS QTNLSPDLSHTTLSPELIQRNLSPALGQMPISPDLSHTTLSPDLSHTTLS LDLSQTNLSPELSQTNLSPALGQMPLSPDLSHTTLSLDFSQTNLSPELSH MTLSPELSQTNLSPALGQMPISPDLSHTTLSLDFSQTNLSPELSQTNLSP ALGQMPLSPDPSHTTLSLDLSQTNLSPELSQTNLSPDLSEMPLFADLSQI PLTPDLDQMTLSPDLGETDLSPNFGQMSLSPDLSQVTLSPDISDTTLLPD LSQISPPPDLDQIFYPSESSQSLLLQEFNESFPYPDLGQMPSPSSPTLND TFLSKEFNPLVIVGLSKDGTDYIEIIPKEEVQSSEDDYAEIDYVPYDDPY KTDVRTNINSSRDPDNIAAWYLRSNNGNRRNYYIAAEEISWDYSEFVQRE TDIEDSDDIPEDTTYKKVVFRKYLDSTFTKRDPRGEYEEHLGILGPIIRA EVDDVIQVRFKNLASRPYSLHAHGLSYEKSSEGKTYEDDSPEWFKEDNAV QPNSSYTYVWHATERSGPESPGSACRAWAYYSAVNPEKDIHSGLIGPLLI CQKGILHKDSNMPMDMREFVLLFMTFDEKKSWYYEKKSRSSWRLTSSEMK KSHEFHAINGMIYSLPGLKMYEQEWVRLHLLNIGGSQDIHVVHFHGQTLL ENGNKQHQLGVWPLLPGSFKTLEMKASKPGWWLLNTEVGENQRAGMQTPF LIMDRDCRMPMGLSTGIISDSQIKASEFLGYWEPRLARLNNGGSYNAWSV EKLAAEFASKPWIQVDMQKEVIITGIQTQGAKHYLKSCYTTEFYVAYSSN QINWQIFKGNSTRNVMYFNGNSDASTIKENQFDPPIVARYIRISPTRAYN RPTLRLELQGCEVNGCSTPLGMENGKIENKQITASSFKKSWWGDYWEPFR ARLNAQGRVNAWQAKANNNKQWLEIDLLKIKKITAIITQGCKSLSSEMYV KSYTIHYSEQGVEWKPYRLKSSMVDKIFEGNTNTKGHVKNFFNPPIISRF IRVIPKTWNQSIALRLELFGCDIY ICAM3 (SEQ ID NO: 26):  >sp|P32942|ICAM3_HUMAN Intercellular adhesion  molecule 3 OS = Homo sapiens GN = ICAM3 PE = 1  SV = 2  MATMVPSVLWPRACWTLLVCCLLTPGVQGQEFLLRVEPQNPVLSAGGSLF VNCSTDCPSSEKIALETSLSKELVASGMGWAAFNLSNVTGNSRILCSVYC NGSQITGSSNITVYRLPERVELAPLPPWQPVGQNFTLRCQVEDGSPRTSL TVVLLRWEEELSRQPAVEEPAEVTATVLASRDDHGAPFSCRTELDMQPQG LGLFVNTSAPRQLRTFVLPVTPPRLVAPRFLEVETSWPVDCTLDGLFPAS EAQVYLALGDQMLNATVMNHGDTLTATATATARADQEGAREIVCNVTLGG ERREARENLTVFSFLGPIVNLSEPTAHEGSTVTVSCMAGARVQVTLDGVP AAAPGQPAQLQLNATESDDGRSFFCSATLEVDGEFLHRNSSVQLRVLYGP KIDRATCPQHLKWKDKTRHVLQCQARGNPYPELRCLKEGSSREVPVGIPF FVNVTHNGTYQCQASSSRGKYTLVVVMDIEAGSSHFVPVFVAVLLTLGVV TIVLALMYVFREHQRSGSYHVREESTYLPLTSMQPTEAMGEEPSRAE IL1B (SEQ ID NO: 15):  >sp|P01584|IL1B_HUMAN Interleukin-1 beta OS = Homo  sapiens GN = IL1B PE = 1 SV = 2  MAEVPELASEMMAYYSGNEDDLFFEADGPKQMKCSFQDLDLCPLDGGIQL RISDHHYSKGFRQAASVVVAMDKLRKMLVPCPQTFQENDLSTFFPFIFEE EPIFFDTWDNEAYVHDAPVRSLNCTLRDSQQKSLVMSGPYELKALHLQGQ DMEQQVVFSMSFVQGEESNDKIPVALGLKEKNLYLSCVLKDDKPTLQLES VDPKNYPKKKMEKRFVFNKIEINNKLEFESAQFPNWYISTSQAENMPVFL GGTKGGQDITDFTMQFVSS LEPR (SEQ ID NO: 16):  >sp|P48357|LEPR_HUMAN Leptin receptor OS = Homo sapiens GN = LEPR PE = 1 SV = 2  MICQKFCVVLLHWEFIYVITAFNLSYPITPWRFKLSCMPPNSTYDYFLLP AGLSKNTSNSNGHYETAVEPKFNSSGTHFSNLSKTTFHCCFRSEQDRNCS LCADNIEGKTFVSTVNSLVFQQIDANWNIQCWLKGDLKLFICYVESLFKN LFRNYNYKVHLLYVLPEVLEDSPLVPQKGSFQMVHCNCSVHECCECLVPV PTAKLNDTLLMCLKITSGGVIFQSPLMSVQPINMVKPDPPLGLHMEITDD GNLKISWSSPPLVPFPLQYQVKYSENSTTVIREADKIVSATSLLVDSILP GSSYEVQVRGKRLDGPGIWSDWSTPRVFTTQDVIYFPPKILTSVGSNVSF HCIYKKENKIVPSKEIVWWMNLAEKIPQSQYDVVSDHVSKVTFFNLNETK PRGKFTYDAVYCCNEHECHHRYAELYVIDVNINISCETDGYLTKMTCRWS TSTIQSLAESTLQLRYHRSSLYCSDIPSIHPISEPKDCYLQSDGFYECIF QPIFLLSGYTMWIRINHSLGSLDSPPTCVLPDSVVKPLPPSSVKAEITIN IGLLKISWEKPVFPENNLQFQIRYGLSGKEVQWKMYEVYDAKSKSVSLPV PDLCAVYAVQVRCKRLDGLGYWSNWSNPAYTVVMDIKVPMRGPEFWRIIN GDTMKKEKNVTLLWKPLMKNDSLCSVQRYVINHHTSCNGTWSEDVGNHTK FTFLVVTEQAHTVTVLAINSIGASVANFNLTFSWPMSKVNIVQSLSAYPL NSSCVIVSWILSPSDYKLMYFIIEWKNLNEDGEIKWLRISSSVKKYYIHD HFIPIEKYQFSLYPIFMEGVGKPKIINSFTQDDIEKHQSDAGLYVIVPVI ISSSILLLGTLLISHQRMKKLFWEDVPNPKNCSWAQGLNFQKPETFEHLF IKHTASVTCGPLLLEPETISEDISVDTSWKNKDEMMPTTVVSLLSTTDLE KGSVCISDQFNSVNFSEAEGTEVTYEDESQRQPFVKYATLISNSKPSETG EEQGLINSSVTKCFSSKNSPLKDSFSNSSWEIEAQAFFILSDQHPNIISP HLTFSEGLDELLKLEGNFPEENNDKKSIYYLGVTSIKKRESGVLLTDKSR VSCPFPAPCLFTDIRVLQDSCSHFVENNINLGTSSKKTFASYMPQFQTCS TQTHKIMENKMCDLTV  MAP2K2 (SEQ ID NO: 17):  >sp|P36507|MP2K2_HUMAN Dual specificity mitogen- activated protein kinase kinase 2  OS = Homo sapiens GN = MAP2K2 PE = 1 SV = 1  MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQ KKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMAR KLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHM DGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNI LVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDI WSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRP PGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCL IKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV  MAPK11 (SEQ ID NO: 18):  >sp|Q15759|MK11_HUMAN Mitogen-activated protein  kinase 11 OS = Homo sapiens GN = MAPK11 PE = 1  SV = 2  MSGPRAGFYRQELNKTVWEVPQRLQGLRPVGSGAYGSVCSAYDARLRQKV AVKKLSRPFQSLIHARRTYRELRLLKHLKHENVIGLLDVFTPATSIEDFS EVYLVTTLMGADLNNIVKCQALSDEHVQFLVYQLLRGLKYIHSAGIIHRD LKPSNVAVNEDCELRILDFGLARQADEEMTGYVATRVVYRAPEIMLNWMH YNQTVDIWSVGCIMAELLQGKALFPGSDYIDQLKRIMEVVGTPSPEVLAK ISSEHARTYIQSLPPMPQKDLSSIFRGANPLAIDLLGRMLVLDSDQRVSA AEALAHAYFSQYHDPEDEPEAEPYDESVEAKERTLEEWKELTYQEVLSFK PPEPPKPPGSLEIEQ PIGR (SEQ ID NO: 19):  >sp|P01833|PIGR_HUMAN Polymeric immunoglobulin  receptor OS = Homo sapiens GN = PIGR PE = 1 SV = 4  MLLFVLTCLLAVFPAISTKSPIFGPEEVNSVEGNSVSITCYYPPTSVNRH TRKYWCRQGARGGCITLISSEGYVSSKYAGRANLTNFPENGTFVVNIAQL SQDDSGRYKCGLGINSRGLSFDVSLEVSQGPGLLNDTKVYTVDLGRTVTI NCPFKTENAQKRKSLYKQIGLYPVLVIDSSGYVNPNYTGRIRLDIQGTGQ LLFSVVINQLRLSDAGQYLCQAGDDSNSNKKNADLQVLKPEPELVYEDLR GSVTFHCALGPEVANVAKFLCRQSSGENCDVVVNTLGKRAPAFEGRILLN PQDKDGSFSVVITGLRKEDAGRYLCGAHSDGQLQEGSPIQAWQLFVNEES TIPRSPTVVKGVAGGSVAVLCPYNRKESKSIKYWCLWEGAQNGRCPLLVD SEGWVKAQYEGRLSLLEEPGNGTFTVILNQLTSRDAGFYWCLTNGDTLWR TTVEIKIIEGEPNLKVPGNVTAVLGETLKVPCHFPCKFSSYEKYWCKWNN TGCQALPSQDEGPSKAFVNCDENSRLVSLTLNLVTRADEGWYWCGVKQGH FYGETAAVYVAVEERKAAGSRDVSLAKADAAPDEKVLDSGFREIENKAIQ DPRLFAEEKAVADTRDQADGSRASVDSGSSEEQGGSSRALVSTLVPLGLV LAVGAVAVGVARARHRKNVDRVSIRSYRTDISMSDFENSREFGANDNMGA SSITQETSLGGKEEFVATTESTTETKEPKKAKRSSKEEAEMAYKDFLLQS STVAAEAQDGPQEA RGMB (SEQ ID NO: 20):  >sp|Q6NW40|RGMB_HUMAN RGM domain family member B  OS = Homo sapiens GN = RGMB PE = 1 SV = 3  MGLRAAPSSAAAAAAEVEQRRSPGLCPPPLELLLLLLFSLGLLHAGDCQQ PAQCRIQKCTTDFVSLTSHLNSAVDGFDSEFCKALRAYAGCTQRTSKACR GNLVYHSAVLGISDLMSQRNCSKDGPTSSTNPEVTHDPCNYHSHAGAREH RRGDQNPPSYLFCGLFGDPHLRTFKDNFQTCKVEGAWPLIDNNYLSVQVT NVPVVPGSSATATNKITIIFKAHHECTDQKVYQAVTDDLPAAFVDGTTSG GDSDAKSLRIVERESGHYVEMHARYIGTTVFVRQVGRYLTLAIRMPEDLA MSYEESQDLQLCVNGCPLSERIDDGQGQVSAILGHSLPRTSLVQAWPGYT LETANTQCHEKMPVKDIYFQSCVFDLLTTGDANFTAAAHSALEDVEALHP RKERWHIFPSSGNGTPRGGSDLSVSLGLTCLILIVFL  STK17B (SEQ ID NO: 21):  >sp|O94768|ST17B_HUMAN Serine/threonine-protein  kinase 17B OS = Homo sapiens GN = STK17B PE = 1  SV = 1  MSRRRFDCRSISGLLTTTPQIPIKMENFNNFYILTSKELGRGKFAVVRQC ISKSTGQEYAAKFLKKRRRGQDCRAEILHEIAVLELAKSCPRVINLHEVY ENTSEIILILEYAAGGEIFSLCLPELAEMVSENDVIRLIKQILEGVYYLH QNNIVHLDLKPQNILLSSIYPLGDIKIVDFGMSRKIGHACELREIMGTPE YLAPEILNYDPITTATDMWNIGIIAYMLLTHTSPFVGEDNQETYLNISQV NVDYSEETFSSVSQLATDFIQSLLVKNPEKRPTAEICLSHSWLQQWDFEN LFHPEETSSSSQTQDHSVRSSEDKTSKSSCNGTCGDREDKENIPEDSSMV SKRFRFDDSLPNPHELVSDLLC STX1A (SEQ ID NO: 22):  >sp|Q16623|STX1A_HUMAN Syntaxin-1A  OS = Homo sapiens GN = STX1A PE = 1 SV = 1  MKDRTQELRTAKDSDDDDDVAVTVDRDRFMDEFFEQVEEIRGFIDKIAEN VEEVKRKHSAILASPNPDEKTKEELEELMSDIKKTANKVRSKLKSIEQSI EQEEGLNRSSADLRIRKTQHSTLSRKFVEVMSEYNATQSDYRERCKGRIQ RQLEITGRTTTSEELEDMLESGNPAIFASGIIMDSSISKQALSEIETRHS EIIKLENSIRELHDMFMDMAMLVESQGEMIDRIEYNVEHAVDYVERAVSD TKKAVKYQSKARRKKIMIIICCVILGIVIASTVGGIFA  TEK (SEQ ID NO: 23):  >sp|Q02763|TIE2_HUMAN Angiopoietin-1 receptor  OS = Homo sapiens GN = TEK PE = 1 SV = 2  MDSLASLVLCGVSLLLSGTVEGAMDLILINSLPLVSDAETSLTCIASGWR PHEPITIGRDFEALMNQHQDPLEVTQDVTREWAKKVVWKREKASKINGAY FCEGRVRGEAIRIRTMKMRQQASFLPATLTMTVDKGDNVNISFKKVLIKE EDAVIYKNGSFIHSVPRHEVPDILEVHLPHAQPQDAGVYSARYIGGNLFT SAFTRLIVRRCEAQKWGPECNHLCTACMNNGVCHEDTGECICPPGFMGRT CEKACELHTFGRTCKERCSGQEGCKSYVFCLPDPYGCSCATGWKGLQCNE ACHPGFYGPDCKLRCSCNNGEMCDRFQGCLCSPGWQGLQCEREGIQRMTP KIVDLPDHIEVNSGKFNPICKASGWPLPTNEEMTLVKPDGTVLHPKDFNH TDHFSVAIFTIHRILPPDSGVWVCSVNTVAGMVEKPFNISVKVLPKPLNA PNVIDTGHNFAVINISSEPYFGDGPIKSKKLLYKPVNHYEAWQHIQVTNE IVTLNYLEPRTEYELCVQLVRRGEGGEGHPGPVRRFTTASIGLPPPRGLN LLPKSQTTLNLTWQPIFPSSEDDFYVEVERRSVQKSDQQNIKVPGNLTSV LLNNLHPREQYVVRARVNTKAQGEWSEDLTAWTLSDILPPQPENIKISNI THSSAVISWTILDGYSISSITIRYKVQGKNEDQHVDVKIKNATITQYQLK GLEPETAYQVDIFAENNIGSSNPAFSHELVTLPESQAPADLGGGKMLLIA ILGSAGMTCLTVLLAFLIILQLKRANVQRRMAQAFQNVREEPAVQFNSGT LALNRKVKNNPDPTIYPVLDWNDIKFQDVIGEGNFGQVLKARIKKDGLRM DAAIKRMKEYASKDDHRDFAGELEVLCKLGHHPNIINLLGACEHRGYLYL AIEYAPHGNLLDFLRKSRVLETDPAFAIANSTASTLSSQQLLHFAADVAR GMDYLSQKQFIHRDLAARNILVGENYVAKIADFGLSRGQEVYVKKTMGRL PVRWMAIESLNYSVYTTNSDVWSYGVLLWEIVSLGGTPYCGMTCAELYEK LPQGYRLEKPLNCDDEVYDLMRQCWREKPYERPSFAQILVSLNRMLEERK TYVNTTLYEKFTYAGIDCSAEEAA TNFRSF17 (SEQ ID NO: 24):  >sp|Q02223|TNR17_HUMAN Tumor necrosis factor  receptor superfamily member 17 OS = Homo sapiens  GN = TNFRSF17 PE = 1 SV = 2  MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVK GTNAILVVTCLGLSLIISLAVFVLMFLLRKINSEPLKDEFKNTGSGLLGM ANIDLEKSRTGDEIILPRGLEYTVEECTCEDCIKSKPKVDSDHCFPLPAM EEGATILVTTKTNDYCKSLPAALSATEIEKSISAR

Specific proteins according to the invention are preferably also proteins having at least 80%, more preferably at least 90%, even more preferably at least 95% and especially at least 99% sequence homology to the afore described sequences.

As further described herein, a high level of one or more proteins of a first group of said specific proteins and/or a low level of one or more proteins from a second group of specific proteins is predictive for improved clinical benefit, preferably clinical benefit as described herein, under treatment with at least one pan αv integrin inhibitor, preferably including or consisting of

Abituzumab, for subjects suffering from a bone metastasis disease, including but not limited to metastatic prostate cancer, and metastatic castration-resistant prostate cancer (mCRPC). Preferably, a high level of one or more proteins of a first group of said specific proteins and/or a low level of one or more proteins from a second group of specific proteins is predictive for improved overall survival and/or improved progression free survival, under treatment with at least one pan αv integrin inhibitor, preferably including or consisting of Abituzumab, for subjects suffering from a bone metastasis disease, including but not limited to metastatic prostate cancer, and metastatic castration-resistant prostate cancer (mCRPC).

In an alternatively preferred embodiment, Intetumumab (CNTO-95) can be employed as the at least one pan αv integrin inhibitor in the method according to the invention, instead of Abituzumab.

Said protein levels for said specific proteins are preferably at the same time negative prognostic indicating that the biologically addressed by the markers plays a role both for disease prognosis (summarized in Table 2).

TABLE 1 Clinical outcome dependent on the respective specific protein level under Abituzumab treatment: Patients with benefit have Hazard Ratio High(er) or (HR) Low(er) of Gene plasma progression- symbol levels free survival Logrank (Somamer UniProt compared (PFS) test ID) ID to median [CI 95%] p-value ANG P03950 Low 0.500 0.03 (SL000003) [0.272-0.916] DCN P07585 High 0.443 0.015 (SL004081) [0.235-0.832] F5 P12259 High 0.416 0.01 (SL000622) [0.219-0.790] ICAM3 P32942 High 0.427 0.0059 (SL003178) [0.239-0.766] IL1B P01584 Low 0.498 0.022 (SL001795) [0.279-0.891] LEPR P48357 Low 0.389 0.0033 (SL003184) [0.211-0.717] MAP2K2 P36507 Low 0.397 0.0023 (SL010501) [0.224-0.702] MAPK11 Q15759 Low 0.321 0.00058 (SL007453) [0.171-0.603] PIGR P01833 High 0.311 0.00046 (SL005797) [0.166-0.582] RGMB Q6NW40 Low 0.457 0.0093 (SL010468) [0.256-0.813] STK17B O94768 High 0.380 0.0078 (SL016566) [0.193-0.747] STX1A Q16623 High 0.250 0.000032 (SL004304) [0.131-0.476] TEK Q02763 High 0.508 0.03 (SL003200) [0.280-0.920] TNFRSF17 Q02223 Low 0.471 0.012 (SL004672) [0.265-0.836

TABLE 2 Clinical outcome, preferably determined by radiologic PFS (rPFS) dependent on the respective specific protein level under SoC treatment: High levels indicate Gene (g)ood, or symbol (p)oor prognosis (Somamer UniProt under SOC ID) ID [HR] ANG P03950 Good (SL000003) [0.698] DCN P07585 Poor (SL004081) [1.5] F5 P12259 Poor (SL000622) [2.11] ICAM3 P32942 Poor (SL003178) [2.60] IL1B P01584 Good (SL001795) [0.43] LEPR P48357 Good (SL003184) [0.419] MAP2K2 P36507 Good (SL010501) [0.346] MAPK11 Q15759 Good (SL007453) [0.274] PIGR P01833 Poor (SL005797) [3.44] RGMB Q6NW40 Good (SL010468) [0.393] STK17B O94768 Poor (SL016566) [4.40] STX1A Q16623 Poor (SL004304) [3.77] TEK Q02763 Poor (SL003200) [1.95] TNFRSF17 Q02223 Good (SL004672) [0.425]

The clinical outcome of patients having tumors and/or metastases (both preferably also referred to as tumour lesions or lesions) is preferably analysed according to response (complete and partial), benefit (response and stable disease), and progressive disease. Lesions are preferably evaluated using Response Evaluation Criteria in Solid Tumors (i.e. RECIST criteria) whereby “complete response” (CR) is preferably defined as the disappearance of the target lesions; “partial response” (PR) is preferably defined as at least a 30% decrease in the sum of the longest iron metre of target lesions, preferably taking as reference the baseline sum longest diameter; “progressive disease” (PD) is preferably defined as at least a 20% increase in the sum of the longest diameter of target lesions, preferably taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions; and “stable disease” (SD) is preferably defined as neither sufficient shrinkage to qualify for partial response nor sufficient increased to qualify for progressive disease, preferably taking as reference the smallest sum longest diameter since the treatment started.

Preferably, the at least one pan αv integrin inhibitor, preferably Abituzumab or Intetumumab (CNTO-95), is administered to said subject in combination with one or more chemotherapeutic agents.

Treatment of prostate cancer and/or metastases thereof may involve surgery (e.g. radical prostatectomy), radiation therapy including brachytherapy (prostate brachytherapy) and external beam radiation therapy, high-intensity focused ultrasound (HIFU), chemotherapy, oral chemotherapeutic drugs (Temozolomide/TMZ), cryosurgery, hormonal therapy, or combinations thereof.

Most hormone dependent cancers become refractory after one to three years and resume growth despite hormone therapy. Previously considered “hormone-refractory prostate cancer” or “androgen-independent prostate cancer”, the term castration-resistant has replaced “hormone refractory” because while they are no longer responsive to castration treatment (reduction of available androgen/testosterone/DHT by chemical or surgical means), these cancers still show reliance upon hormones for androgen receptor activation. However, there are now several chemotherapeutic treatments available to treat CRPC that improve survival.

Chemotherapeutics in this respect preferably include, but are not limited to docetaxel, cabazitaxel, bevacizumab, docetaxel, thalidomide and prednisone, and combinations thereof. E.g., a combination of bevacizumab, docetaxel, thalidomide and prednisone has shown clinical benefits.

Chemotherapeutics in this respect preferably also include, but are not limited to, cetuximab, Panitumumab, irinotecan, vinorelbine, capecitabine, leucovorine, oxaliplatin, cisplatin, carboplatin, 5-fluorouracil (5-FU), bevacizumab, aflibercept and regorafenib.

More preferably, one or more chemotherapeutic agents, even more preferably two or more and especially one, two or three chemotherapeutic agents

a) selected from the group consisting of leuproreline acetate, bicalutamide, nilutamide, triptoreline, gosereline, flutamide, cyproterone, busereline and degarelix, b) selected from the group consisting of Zoledronic acid, Pamidronic acid, Clodronate disodium, Alendronic acid and Ibandronic acid, and/or c) selected from the group consisting of Abiraterone, Abiraterone acetate, Prednisone, Enzalutamide, Radium Ra 223 dichloride, Docetaxel, Sipuleucel-T, Cabazitaxel and Mitoxantrone, are employed. This is preferred for subjects suffering from a bone metastasis disease, more preferred for subjects suffering from metastatic prostate cancer, and especially for subjects suffering from metastatic castration-resistant prostate cancer (mCRPC).

A subset of subjects appears to respond to androgen signaling blocking drugs, including, but not limited to Luteinizing hormone-releasing hormone (LH-RH) agonists and/or antagonists as well as gonadotropin-releasing hormone (GnRH) agonists and/or antagonists. Luteinizing hormone-releasing hormone (LH-RH) as well as gonadotropin-releasing hormone (GnRH) are hormone therapy drugs that lower the production of testosterone in a man's body. This drop in testosterone usually slows or stops the growth of prostate cancer for a period of time. Thus, it is in many cases preferred to administer this class of compounds in connection with treatment with Abituzumab or Intetumumab (CNTO-95).

Further agents that are preferably regarded as chemotherapeutics in the context of the instant invention include sipuleucel-T, abiraterone and Enzalutamide.

Pain is common in metastatic cancers and especially in case of bone metastases thereof. This is also true with prostate cancer, and cancer pain related to bone metastases can be treated with bisphosphonates, medications such as opioids, and palliative radiation therapy to known metastases. Spinal cord compression can occur with metastases to the spine, and can be treated with steroids, surgery, or radiation therapy. The traditional treatments for cancer are Radiotherapy and chemotherapy, usually in combination with one another. Scientists and pharmaceutical companies are researching drugs to target different types of cancer, including metastatic bone disease.

High-intensity focused ultrasound (HIFU) has CE approval for palliative care for bone metastasis. As an entirely side-effect free and non-invasive treatment, HIFU has been successfully applied in the treatment of cancer to destroy tumours of the bone, brain, breast, liver, pancreas, rectum, kidney, testes, and prostate.

One treatment option for bone metastases that has to be considered is treatment with bisphosphonates, often in combination of other chemotherapeutics and/or (anti-)hormonal treatment. Bisphosphonates have shown great promise in reducing bone cancer pain, bone destruction, and tumor growth.

Monthly injections of radium-223 chloride (as Xofigo, formerly called Alpharadin) have been approved by the FDA in May 2013 for castration-resistant prostate cancer (CRPC) with bone metastases.

Especially preferably, the at least one pan αv integrin inhibitor, preferably Abituzumab or Intetumumab (CNTO-95), more preferably Abituzumab, is administered to said subject in combination with two or more chemotherapeutic agents, preferably referred to as standards of care (SoC).

Preferred standards of care (SoC) include, but are not limited to:

a) at least one LHRH agonist/antagonist, preferably selected from the group consisting of Leuproreline, Leuproreline acetate, bicalutam id, nilutamide, triptoreline, gosereline, flutamide, cyproterone, busereline and degarelix, and/or b) at least one bisphosphonate, preferably selected from the group consisting of Zoledronic acid, Pamidronic acid, Clodronate disodium,

Alendronic acid and Ibandronic acid.

More preferred standards of care (SoC) include, but are not limited to:

-   a) at least one LHRH agonist/antagonist, preferably selected from     the group consisting of Leuproreline, Leuproreline acetate,     bicalutam id, nilutamide, triptoreline, gosereline, flutamide,     cyproterone, busereline and degarelix, and/or the pharmaceutically     acceptable derivatives and/or salts thereof; in combination with -   b) at least one bisphosphonate, preferably selected from the group     consisting of Zoledronic acid, Pamidronic acid, Clodronate disodium,

Alendronic acid and Ibandronic acid, and/or the pharmaceutically acceptable derivatives and/or salts thereof.

The most preferred standard of care (SoC) includes:

a) Leuproreline, Leuproreline acetate and/or pharmaceutically acceptable derivatives and/or salts thereof, in combination with b) Zoledronic acid and/or pharmaceutically acceptable derivatives and/or salts thereof.

αv integrins are cell adhesion molecules involved in cell survival, proliferation, migration, and angiogenesis; they are deregulated in various cancer types, including prostate cancer (Legate K R, et al. Nat Rev Mol Cell Biol 2006; 7:20-31; Guise T A, et al. Clin Cancer Res 2006; 12:6213s-16s). Abituzumab, a humanized monoclonal IgG2 antibody, inhibits αv-integrins expressed on castrate-resistant prostate cancer (CRPC) cells, tumor vessels, and osteoclasts involved in bone metastasis (Mitjans F, et al. J Cell Sci 1995; 108:2825-38; Monnier Y, et al. Cancer Res 2008; 68:7323-31). Abituzumab demonstrated antitumor activity in in vivo CRPC models and was well tolerated in a phase I study in mCRPC patients previously treated with docetaxel (Wirth M, et al. Eur Urol 2014; 65:897-904).

In an randomized, double-blind, placebo-controlled, phase II trial, a total of 180 patients were randomized 1:1:1 to receive

-   -   a) standard of care (SoC), e.g. continuous treatment with a         luteinizing hormone-releasing hormone agonist and bisphosphonate         treatment, e.g. with Leuproreline or Leuproreline acetate and         Zoledronic acid (and/or pharmaceutically acceptable derivatives         and/or salts thereof) plus placebo,     -   b) SoC as described under a) plus abituzumab 750 mg, or     -   c) SoC as described under a) plus abituzumab 1,500 mg.     -   Patients were treated until rPD in bone or soft tissue lesions,         skeletal event, death, or unacceptable toxicity; Patients in the         placebo arm who had asymptomatic or mildly symptomatic rPD on         treatment could crossover to abituzumab 1,500 mg (open-label).

Median PFS with abituzumab 1,500 mg was modestly longer than with abituzumab 750 mg or placebo: 4.3 (95% CI: 2.8-6.6) vs 3.4 (95% CI: 2.8-5.6) and 3.3 (95% CI: 2.8-4.8) months; HR abituzumab 1,500 mg vs placebo: 0.81 (95% CI: 0.52-1.26). Patients receiving abituzumab experienced bone progression less frequently than those receiving placebo (23% of patients receiving abituzumab had bone progression, vs 42% of those receiving SoC).

Blood sampling for plasma protein analyses was scheduled pre-treatment. Plasma protein analyses (based on highly protein-specific aptamers [SomaLogic system]) were performed on samples taken from 150 patients prior to treatment in cycle 1.

The original set of simultaneously determined 1,129 plasma protein levels was restricted to 888 proteins on the data level to αvoid potential bias due to cell lysis or platelet activation during plasma preparation. Nine global biomarker search analyses were carried out using different normalization procedures, data sets and biomarker dichotomization thresholds, with the aim of filtering specific proteins that are predictive biomarkers for Abituzumab therapy success. The judgement whether a distinct protein is a predictive biomarker was based on an assessment of outcome (OS or PFS) in dependence of treatment (SoC or Abituzumab) and biomarker levels (continuous levels, and dichotomized categories “high” and “low” using the median of the investigated patient population as a threshold). Statistical tests were carried out per protein to identify those proteins that can be considered as predictive. The statistical tests are prior art and comprised. Among other criteria, logrank tests on selected populations, as for example the biomarker “high” and biomarker “low” populations, for detection of differences in outcome (here OS and/or PFS) for different treatment groups (Abituzumab and SOC; threshold p<=0.05), and Cox regression models investigating dependence of outcome on the interaction effect between treatment and continuous marker levels (interaction term p<=0.05). Further, the prognosticity of the marker levels was assessed on the basis of the patient group receiving SOC therapy using logrank tests (threshold p<=0.05) for the “high” and “low” subgroups.

Said specific proteins include decorin (DCN), a protein known to have a role in TGF-β biology, as do some of the αv integrins inhibited by abituzumab (Munger J S, Sheppard D. Cold Spring Harb Perspect Biol 2011; 3:a005017).

Furthermore, analysis of the biological context of other markers indicated that markers related to known molecular interactions of abituzumab (bone metabolism modulation and angiogenesis) appear to predict OS and/or PFS with abituzumab therapy.

Thus, plasma levels of each of the identified biomarker plasma proteins were surprisingly found to be prognostic of poor survival and predicted increased survival and/or progression free survival with abituzumab compared to SoC alone.

Thus, the clinical study delivered data on the pharmacokinetics and immunogenicity of abituzumab, as well as enabled analyses in search of predictive biomarkers, and surprisingly provided specific predictive protein levels in body fluids, especially specific plasma protein levels that allow predicting the therapy outcome under treatment with at least one pan αv integrin inhibitor, preferably including the pan αv integrin inhibitor abituzumab.

Abituzumab is a monoclonal anti-alpha v antibody also designated herein as DI-17E6, DI17E6, EMR62242 and/or EMD 525797).

DI17E6 is an engineered specifically tailored IgG2 hybrid monoclonal antibody directed to alpha-v integrin (receptor). Cancer therapy by means of this antibody reduces side effects associated with this type of therapy, above all immune reactions, thereby reducing immunogenicity. The antibody is described in detail in WO 2009/010290, the disclosure of which is encorporated herein in its entirety.

Its hypervariable regions (CDRs) derive from murine mAb 17E6 (EMD 73034). This parent mouse IgG1 antibody is described, for example by Mitjans et al. (1995; J.Cell Sci. 108, 2825) and patents U.S. Pat. No. 5,985,278 and EP 719 859. Mouse mAb 17E6 is produced by hybridoma cell line 272-17E6 and deposited under accession number DSM ACC2160.

Its light chain domains derive from humanized monoclaonal anti-EGFR antibody 425 (matuzumab). This antibody is described in detail for example in EP 0 531 47261, and derives from its murine counterpart 425 (mouse MAb 425, ATCC HB9629), The antibody was raised against the human A431 carcinoma cell line and found to bind to a polypeptide epitope on the external domain of the human epidermal growth factor receptor (EGFR). Matuzumab has shown in clinical trials high efficacy.

-   -   Generally DI17E6 as used according to the invention comprises:     -   (i) a CDR light and a heavy chain region deriving from mouse         monoclonal anti-αv integrin antibody 17E6     -   (ii) a light chain framework region which is taken from         humanized monoclonal anti-EGFR antibody 425,     -   (iii) a heavy chain framework region deriving from mouse         monoclonal anti-αv integrin antibody 17E6, optionally comprising         one or more mutations of amino acids at specific positions, and     -   (iv) a heavy chain constant region deriving from human IgG2 and         a human constant kappa light chain region, wherein in said IgG2         domain the IgG2 hinge region was replaced by the human IgG1         hinge domain, and;     -   wherein optionally one or more mutations within the IgG2 has         been carried out.     -   Specifically, DI17E6 (designated as “DI-17E6y2h(N297Q)” or “EMD         525797”) as used for the treatment as described and in the         clinical trials as described above and below, has the following         amino acid sequence:

(i) variable and constant light chain sequences (SEQ ID No. 1): DIQMTQSPSSLSASVGDRVTITC 

WYQQKPGKAPKLLIY

GVPSRFSGSGSGTDYTFTISSLQPEDIATYYC 

FGQGTKV EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK SFNRGEC and (ii)variable and constant heavy chain sequences (SEQ ID No.2): QVQLQQSGGELAKPGASVKVSCKASGYTFS 

WVRQAPGQGLEWIG 

RSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCAS

WGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT VSWNSGALISGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPS NTKVDKTVEPKSSDKTHTCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQAQSTFRVVSVLTVVHQ DWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK, 

-   -   wherein the underlined sequences represent the variable regions         with the CDRs (in bold, identical with the parent mouse         antibody). The modified IgG1 hinge region is represented by         EPKSSDKTHTCPPCP (SEQ ID No. 3), and AQ is a substitution within         the IgG2 domain.     -   However, as it was shown in WO 2009/010290, also variants of         DI17E6 can be used according to the teaching of this invention.         Thus, DI17E6 variants comprising one or more modifications         within the heavy chain framework regions

(SEQ ID No. 27) FR1: QVQLQQSG

ELA

PGASVK

SCKASGYTFS (SEQ ID No. 28) FR2: WV

Q

PGQGLEWIG (SEQ ID No. 29) FR3: KATMT

DTS

STAYM

LS

L

SED

AVYYCAS (SEQ ID No. 30) FR4: WGQGT

VTVSS,

-   -   wherein one or more of the bold and underlined positions are         mutated, can be used in the treatment of prostate cancer         patients as described. In more detail, the following position         heavy chain framework region is mutated at one, more or all of         the following positions can be mutated: A9, E13, M20, K38, R40,         A72, S76, Q82, G85, T87, S91 and S113. These variants show the         same or very similar biological activity and efficacy as         compared to DI17E6 defined by its sequences above.     -   In general, the invention as described includes also         modifications and variants of the DI17E6 antibody that are         functionally and/or pharmaceutically identical or similar to         unmodified DI17E6, and wherein the CDR regions and heavy and         light chain variable regions are at least 80%, or at least 85%,         or at least 90%, or at least 95% identical in their amino acid         sequence compared to the respective variable regions of DI17E6.         In addition, the invention also includes modifications and         variants of the DI17E6 antibody that are functionally and/or         pharmaceutically identical or similar to unmodified DI17E6, and         wherein the constant regions are at least 80%, or at least 85%,         or at least 90%, or at least 98% identical in their amino acid         sequence compared to the respective constant regions of DI17E6.         Changes is the constant regions of the IgG chains of the         antibody may improve specific properties like immunogenicity,         ADCC, and so on.     -   Thus, for use according the invention, also functional         derivatives, biologically active variants or modifications of         DI17E6 can be employed.     -   Accordingly, in the context of the present invention, the terms         “Abituzumab” and/or “DI17E6” preferably also comprise:     -   a biologically active variant or modification thereof that         comprises the CDR regions and heavy and light chain variable         regions, which are 80%-95% identical in amino acid sequence         compared to the variable regions of Abituzumab;     -   a biologically active variant or modification that comprises a         constant region, which is at least 80%-98% identical with the         amino acid sequence compared to the constant region of         Abituzumab;     -   an antibody that comprises one or more modifications within the         heavy chain framework regions

(SEQ ID No. 27) FR1: QVQLQQSG

ELA

PGASVK

SCKASGYTFS (SEQ ID No. 28) FR2: WV

Q

PGQGLEWIG (SEQ ID No. 29) FR3: KATMT

DTS

STAYM

LS

L

SED

AVYYCAS (SEQ ID No. 30) FR4: WGQGT

VTVSS,

-   -   wherein one or more of the bold and underlined positions are         mutated and are different compared to the original respective         sequence of abituzumab;     -   and/or     -   a modified DI17E6 antibody comprising a human IgG1 constant         region instead of human IgG2, or a human IgG2 hinge region         instead of the human IgG1 hinge.

Intetumumab or CNTO-95 is a human monoclonal antibody, preferably used in the treatment of solid tumors. It is also an anti-αv integrin antibody, which is preferably comprising human heavy chain and human light chain variable regions comprising the amino acid sequences as shown in SEQ ID NO: 8 and SEQ ID NO: 9, respectively, as shown below:

SEQ ID NO: 8       8       119       PRT       Artificial Sequence       Sequence 7 from U.S. Pat. No. 7,550,142       8 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1               5                   10                  15 Ser Arg Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr             20                  25                  30 Thr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val         35                  40                  45 Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val     50                  55                  60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr 65                   70                 75                  80 Leu Gln Val Asn Ile Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                 85                  90                  95 Ala Arg Glu Ala Arg Gly Ser Tyr Ala Phe Asp Ile Trp Gly Gln Gly             100                 105                 110 Thr Met Val Thr Val Ser Ser         115 SEQ ID NO: 9       9       108       PRT       Artificial Sequence       Sequence 8 from U.S. Pat. No. 7,550,142       9 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1               5                   10                  15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr             20                  25                  30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile         35                  40                  45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly     50                  55                  60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65                  70                  75                  80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro                 85                  90                  95 Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys             100                 105 and/or LOCUS ABN29020               119 aa linear   PAT 07-FEB-2007 DEFINITION Sequence 7 from U.S. Pat. No. 7163681. ACCESSION ABN29020 VERSION ABN29020.1 GI:125142205 DBSOURCE accession ABN29020.1 KEYWORDS . SOURCE Unknown.   ORGANISM Unknown. Unclassified. REFERENCE 1 (residues 1 to 119)   AUTHORS Giles-Komar,J., Snyder,L., Trikha,M. and Nakada,M.T.   TITLE Anti-integrin antibodies, compositions, methods and uses JOURNAL Patent: US 7163681-A 7 16 JAN. 2007; Centocor, Inc.; Malvern, PA; US;   REMARK CAMBIA Patent Lens: US 7163681 FEATURES          Location/Qualifiers      source          1..119          /organism = ″unknown″ ORIGIN         1 qvqlvesggg vvqpgrsrrl scaasgftfs rytmhwvrqa pgkglewvav isfdgsnkyy        61 vdsvkgrfti srdnsently lqvnilraed tavyycarea rgsyafdiwg qgtmvtvss // LOCUS ABN29021 108 aa linear   PAT 07-FEB-2007 DEFINITION Sequence 8 from U.S. Pat. No. 7163681. ACCESSION ABN29021 VERSION ABN29021.1 GI:125142207 DBSOURCE accession ABN29021.1 KEYWORDS . SOURCE Unknown.   ORGANISM Unknown. Unclassified. REFERENCE 1 (residues 1 to 108)   AUTHORS Giles-Komar,J., Snyder,L., Trikha,M. and Nakada,M.T.   TITLE Anti-integrin antibodies, compositions, methods and uses JOURNAL Patent: US 7163681-A 8 16 JAN. 2007; Centocor, Inc.; Malvern, PA; US;   REMARK CAMBIA Patent Lens: US 7163681 FEATURES          Location/Qualifiers      source          1..108          /organism = ″unknown″      Region          2..107          /region_name = ″IgV_L_kappa″          /note = ″Immunoglobulin (Ig) light chain, kappa type,          variable (V) domain; cd04980″          /db_xref = ″CDD:143181″      Region          8..100          /region_name = ″IG_like″          /note = ″Immunoglobulin like; smart00410″          /db_xref = ″CDD:214653″      Site          order(12,104,106..107)          /site_type = ″other″          /note = ″intrachain domain interface″          /db_xref = ″CDD:143181″      Site          25..27          /site_type = ″other″          /note = ″L1 hypervariable region″          /db_xref = ″CDD:143181″      Site          order(32,49,93)          /site_type = ″other″          /note = ″antigen binding site          /db_xref = ″CDD:143181″      Site          order(34,36,38,43,46,50,87)          /site_type = ″other″          /note = ″heterodimer interface [polypeptide binding]″          /db_xref = ″CDD:143181″      Site          66..70          /site_type = ″other″          /note = ″L2 hypervariable region″          /db_xref = ″CDD:143181″      Site          order(92..94,96..98)          /site_type = ″other″          /note = ″L3 hypervariable region″          /db_xref = ″CDD:143181″ ORIGIN         1 eivltqspat lslspgerat lscrasqsys sylawyqqkp gqaprlliyd asnratgipa        61 rfsgsgsgtd ftltisslep edfavyycqq rsnwppftfg pgtkvdik //

Intetumumab is further characterised in WO02/12501 and U.S. Pat. No. 7,163,681, the disclosure of which is incorporated in their entirety into this application by reference.

Preferably, also functional derivatives, biologically active variants or modifications of Intetumumab can be employed in the instant invention.

For ease of use, the one or more proteins that are preferably active as biomarkers in the context of the present invention, i.e.

DCN (Somamer ID: SL004081; UniProt ID: P07585), F5 (Somamer ID: SL000622; UniProt ID: P12259), ICAM3 (Somamer ID: SL003178; UniProt ID: P32942), PIGR (Somamer ID: SL005797; UniProt ID: P01833), STK17B (Somamer ID: SL016566; UniProt ID: 094768), STX1A (Somamer ID: SL004304; UniProt ID: Q16623), and TEK (Somamer ID: SL003200; UniProt ID: Q02763),

and/or b) one or more proteins, selected from the group consisting of

ANG (Somamer ID: SL000003; UniProt ID: P03950), IL1B (Somamer ID: SL001795; UniProt ID: P01584), LEPR (Somamer ID: SL003184; UniProt ID: P48357), MAP2K2 (Somamer ID: SL010501; UniProt ID: P36507), MAPK11 (Somamer ID: SL007453; UniProt ID: Q15759), RGMB (Somamer ID: SL010468; UniProt ID: Q6NW40), and TNFRSF17 (Somamer ID: SL004672; UniProt ID: Q02223),

are preferably also referred to collectively as “specific proteins” or “said specific proteins” of the present invention, and preferably also referred to individuality as “the specific protein” or “said specific protein”.

As used herein, the term “sequence homology” is understood by the ones skilled in the art, and methods for determining sequence homology are also known in the art.

As used herein, sequence homology is preferably determined using the BLAST algorithm. BLAST preferably stands for for Basic Local Alignment Search Tool and is an algorithm for comparing primary biological sequence information, such as the amino-acid sequences of different proteins or the nucleotides of DNA sequences. A BLAST search enables a researcher to compare a query sequence with a library or database of sequences, and identify library sequences that resemble the query sequence above a certain threshold. The BLAST algorithm and the computer program that implements it were developed by Stephen Altschul, Warren Gish, and David Lipman at the U.S. National Center for Biotechnology Information (NCBI), Webb Miller at the Pennsylvania State University, and Gene Myers at the University of Arizona. It is available on the web on the NCBI website. Alternative implementations include AB-BLAST (formerly known as WU-BLAST), FSA-BLAST (last updated in 2006), and ScalaBLAST.

Different types of BLASTs are available according to the query sequences. For example, following the discovery of a previously unknown gene in the mouse, a scientist will typically perform a BLAST search of the human genome to see if humans carry a similar gene; BLAST will identify sequences in the human genome that resemble the mouse gene based on similarity of sequence. The BLAST algorithm and program were designed by Stephen Altschul, Warren Gish, Webb Miller, Eugene Myers, and David J. Lipman at the NIH and was published in the Journal of Molecular Biology in 1990.

In the context of the present invention, the sequence homology of the proteins described herein is preferably determined on the basis of the longest local alignments generated using BLASTp.

In the context of the present invention, subjects and especially human subjects are preferably also referred to as patients.

As used herein, the term “about” with respect to numbers, amounts, dosings, hours, times, timings, durations, and the like, is preferably understood to mean “approximately” with respect to said numbers, amounts, dosings, hours, times, timings, durations, and the like. More Preferably, the term “about” means +/−10%, more preferably +/−5% of the given specific value with respect to numbers, amounts, dosings, hours, times, timings, durations, and the like.

If not specified otherwise, amounts administered to a subject, human subject or patient given in “mg”, such as in 500 mg, 1000 mg, or the like, are preferably intended to mean the respective amounts to be administered “flat”, i.e. as a fixed dose that is not adjusted to the bodyweight and/or body surface of the respective subject, human subject or patient.

If not explicitly indicated otherwise, the term “one or more” as used herein, e.g. with respect to the number of compounds, agents, cancer cotherapeutic agents, cancer chemotherapeutic agents and the like, preferably means “one or more than one” and thus preferably includes “two or more” (or “two or more than two”), “three or more” (or “three or more than three”) and/or “four more” (or “more or more than four”). Accordingly, the term “one or more” as used herein preferably includes the numbers one, two, three, four, five, six and/or higher numbers. With respect to the number of agents, cancer cotherapeutic agents, cancer chemotherapeutic agents, it especially preferably includes the numbers one, two, three, four and/or five, even more preferably the numbers one, two, three and/or four and especially the numbers one, two and/or three.

Preferably, especially preferred subjects of the instant invention relate to aspects, subjects, uses, methods and/or embodiments, wherein one or more features of two or more of the herein described aspects, subjects, uses, methods and/or embodiments are combined in one subject.

The invention is explained in greater detail below by means of examples. The invention can be carried out throughout the range as described and is not restricted to the examples given here.

The following examples are given in order to assist the skilled artisan to better understand the present invention by way of exemplification. The examples are not intended to limit the scope of protection conferred by the description. The features, properties and advantages exemplified for the compounds and uses defined in the examples may be assigned to other compounds and uses not specifically described and/or defined in the examples, but falling under the scope of the description.

EXPERIMENTAL SECTION Example 1

PERSEUS Phase II Clinical Study

-   c) Leuproreline, Leuproreline acetate and/or pharmaceutically     acceptable derivatives and/or salts thereof, in combination with

Zoledronic acid and/or pharmaceutically acceptable derivatives and/or salts thereof

PERSEUS Phase II clinical trial

In this randomized, double-blind, placebo-controlled, international phase II trial, a total of 180 patients were randomized 1:1:1 to receive

a) Standard of Care (SoC), e.g. continuous treatment with a luteinizing hormone-releasing hormone agonist, preferably Leuproreline, Leuproreline acetate and/or pharmaceutically acceptable derivatives and/or salts thereof, and bisphosphonate treatment, preferably Zoledronic acid and/or pharmaceutically acceptable derivatives and/or salts thereof, plus placebo, b) abituzumab 750 mg plus SoC, or c) abituzumab 1,500 mg plus SoC.

Pharmacokinetic Analysis

-   -   Equal numbers of patients per arm were included in the         pharmacokinetic analysis subgroup.     -   Blood sampling for pharmacokinetic assessments was scheduled at         various timepoints during cycles 1, 3, 4, 5, 6, and 7 of         therapy.     -   Pharmacokinetic parameters were calculated according to standard         non-compartmental methods using the program KINETICA™ v4.1.1         (Innaphase).

Immunogenicity

-   -   Blood sampling for immunogenicity was scheduled pre-dose in         cycles 1, 3, 5 and 6, and at the end-of-treatment visit and         safety follow-up visits.     -   Generation of antibodies directed against abituzumab was         evaluated centrally using a validated ELISA method.

Biomarker Analyses

-   -   Archived tumor blocks or punch biopsy materials were collected         to explore tumor expression of integrins and their ligands as         well as proteins related to angiogenesis and the underlying         disease, and their potential relationship to clinical outcomes.         -   Availability of samples had to be confirmed at patient             screening         -   Analyses were performed using immunohistochemistry.     -   Blood sampling for plasma protein analyses was scheduled         pre-treatment.     -   Plasma protein analyses (based on highly protein-specific         aptamers [SomaLogic system]) were performed on samples taken         from 150 patients prior to treatment in cycle 1         -   The original set of simultaneously determined 1,129 plasma             protein levels was restricted to 888 proteins on the data             level to αvoid potential bias due to cell lysis or platelet             activation during plasma preparation         -   Nine global biomarker search analyses were carried out using             different normalization procedure, data sets and biomarker             dichotomization thresholds, with the aim of filtering             biomarker proteins based on data robustness independent of             biological annotations. The search process comprised a set             of criteria ensuring that identified proteins are             significantly (p<0.05) associated with outcome (here             exemplary radiologic PFS) for either the patients with low             or high levels. These tests comprise, among others, logrank             tests for differences in survival (here PFS) for             Abituzumab-treated/untreated patients in the biomarker-low             and biomarker-high groups according to th median threshold,             tests for an interaction effect on outcome (here PFS)             between continuous marker levels and treatment based on Cox             regression models.         -   This process identified 15 biomarker plasma proteins: DCN             (Somamer ID: SL004081; UniProt ID: P07585),

F5 (Somamer ID: SL000622; UniProt ID: P12259), ICAM3 (Somamer ID: SL003178; UniProt ID: P32942), PIGR (Somamer ID: SL005797; UniProt ID: P01833), STK17B (Somamer ID: SL016566; UniProt ID: 094768), STX1A (Somamer ID: SL004304; UniProt ID: Q16623), TEK (Somamer ID: SL003200; UniProt ID: Q02763), ANG (Somamer ID: SL000003; UniProt ID: P03950), IL1B (Somamer ID: SL001795; UniProt ID: P01584), LEPR (Somamer ID: SL003184; UniProt ID: P48357), MAP2K2 (Somamer ID: SL010501; UniProt ID: P36507), MAPK11 (Somamer ID: SL007453; UniProt ID: Q15759), RGMB (Somamer ID: SL010468; UniProt ID: Q6NW40), and TNFRSF17 (Somamer ID: SL004672; UniProt ID: Q02223)

Results

Biomarker analyses

-   -   IHC analysis of tumor samples has not identified any relevant         biomarkers to date.     -   The details documenting why the 14 biomarker plasma proteins         identified are judged as active and whether levels above or         below the median are judged as predictive are shown in Table 1,         Table 2 and/or one or more of FIGS. 1 to 24.     -   The biomarker proteins include decorin (DCN), a protein known to         have a role in TGF-β biology, as do some of the αv integrins         inhibited by abituzumab     -   Furthermore, analysis of the biological context of other markers         indicated that markers related to known molecular interactions         of abituzumab (bone metabolism modulation and angiogenesis)         appeared to predict OS with abituzumab therapy.     -   Plasma levels of some of the identified 14 biomarker plasma         proteins were prognostic under SoC of either good or poor         survival and all 14 predicted increased survival with abituzumab         compared to SoC alone. Table 1, Table 2 and/or one or more of         FIGS. 1 to 24 show the prognostic and predictive value of the         identified 14 predictive marker proteins, as for example TEK,         for PFS.

Example 2

Proteomic Affinity Assay Method

All steps of the proteomic affinity assay are performed at room temperature unless otherwise indicated.

Sample Thawing and Plating.

Aliquots of 100% serum or EDTA-plasma, stored at −80° C., are thawed by incubating in a 25° C. water bath for ten minutes. After thawing the samples are stored on ice during mixing and prior to sample dilution. Samples are mixed by gentle vortexing (setting #4 on Vortex Genie, Scientific Industries) for 8 seconds. A 20% sample solution is prepared by transferring 16 μL of thawed sample into 96-well plates (Hybaid Omnitube 0.3 mL, ThermoFisher Scientific) containing 64 μL per well of the appropriate sample diluent at 4° C. Sample diluent for serum is 0.8×SB17 with 0.6 mM MgCl₂, 2 mM EGTA, 2 μM Z-Block_2, 0.05% Tween and for EDTA-plasma is 0.8×SB18 with 0.8 mM MgCl₂, 2 mM EGTA, 2 μM Z-Block_2, 0.05% Tween. This plate is stored on ice until the next sample dilution steps are initiated.

Preparation of 10%, 1% and 0.03% SOMAmer Solutions. SOMAmers are grouped into three unique mixes. The placing of a SOMAmer within a mix is empirically determined by assaying a dilution series of serum or plasma with each SOMAmer and identifying the sample dilution that gave the largest linear range of signal. The segregation of SOMAmers and mixing with different dilutions of sample (10%, 1% or 0.03%) allow the assay to span a 10⁷-fold range of protein concentration. The composition of the custom SOMAmer mixes is slightly different between plasma and serum as expected due to variation in protein composition of these two media. The custom stock SOMAmer solutions for 10%, 1% and 0.03% serum and plasma are prepared and stored at 8× concentration in SB17T. For each assay run, the three 8×SOMAmer solutions are diluted separately 1:4 into SB17T to achieve 2× concentration. Each diluted SOMAmer master mix is heated to 95° C. for five minutes and then to 37° C. for 15 minutes. 55 μL of each 2×SOMAmer mix is manually pipetted into a 96-well plate resulting in three plates with 10%, 1% or 0.03% SOMAmer mixes. After mixing with sample, the final individual SOMAmer concentration ranged from 0.25-4 nM for serum, 0.5 nM for plasma.

Equilibration. A 2% sample plate is prepared by diluting the 20% sample 1:10 into SB17T using the Beckman Coulter Biomek Fx^(P) (Beckman Coulter). A 0.06% sample plate is prepared by diluting the 2% sample plate 1:31 into SB17T. The three sample dilutions are then transferred to their respective SOMAmer solutions by adding 55 μL of the sample to 55 μL of the appropriate 2×SOMAmer mix. The plates are sealed with a foil seal (Microseal ‘F’ Foil, Bio-Rad) and incubated at 37° C. for 3.5 hours.

Preparation of Catch-1 Bead Plates. 133.3 μL of a 7.5% Streptavidin-agarose bead slurry in SB17T is added to each well of three pre-washed 0.45 um filter plates. Each well of beads is washed once with 200 μL SB17T using vacuum filtration to remove the wash and then resuspended in 200 μL SB17T.

Catch-1 Bead Capture. All subsequent steps are performed by the Beckman Coulter Biomek Fx^(P) robot unless otherwise noted. After the 3.5 hour equilibration, 100 μL of the 10%, 1% and 0.03% equilibration binding reactions is transferred to their respective Catch-1 Streptavidin agarose filter plates and incubated with shaking for ten minutes. Unbound solution is removed via vacuum filtration. Each set of Catch-1 beads is washed with 190 μL of 100 μM biotin in SB17T and then 190 mL of SB17T using vacuum filtration to remove the wash. 190 μL SB17T is added to each well in the Catch-1 plates and incubated with shaking for ten minutes at 25° C. The wash is removed via vacuum filtration and the bottom of the filter plates blotted to remove droplets using the on-deck blot station.

Biotinylation of Proteins. An aliquot of 100 mM NHS-PEO4-biotin in DMSO is thawed at 37° C. for six minutes and diluted to 1 mM with SB17T at pH 7.25. 100 μL of the NHSPEO4-biotin is added to each well of each Catch-1 filter plate and incubated with shaking for five minutes. Each biotinylation reaction is quenched by adding 150 μL of 20 mM glycine in SB17T to the Catch-1 plates with the NHS-PEO4-biotin. Plates are incubated for one minute with shaking, vacuum filtrated, and 190 μL 20 mM glycine SB17T is added to each well in the plate. The plates are incubated for one minute, shaking before removal by vacuum filtration. 190 μL of SB17T is added to each well and removed by vacuum filtration. The wells of the Catch-1 plates are subsequently washed three times by adding 190 μL SB17T, incubating for one minute with shaking followed by vacuum filtration. After the last wash the plates are centrifuged at 1000 rpm for one minute over a 1 mL deep-well plate to remove extraneous volume before elution. Centrifugation is performed off deck.

Kinetic Challenge and Photo-Cleavage. 85 μL of 10 mM dextran sulfate in SB17T is added to each well of the filter plates. The filter plates are placed onto a Thermal Shaker (Eppendorf) under a BlackRay light source and irradiated for ten minutes with shaking. The photo-cleaved solutions are sequentially eluted from each Catch-1 plate into a common deep well plate by centrifugation at 1000 rpm for one minute each.

Catch-2 Bead Capture. In bulk, MyOne-Streptavidin C1 beads are washed two times for 5 minutes each with equal volume of 20 mM NaOH and three times with an equal volume of SB17T. Beads are resuspended in SB17T to a concentration of 10 mg/mL. After resuspension, 50 μL of this solution is manually pipetted into each well of a 96-well plate and stored at 4° C. until Catch-2. During Catch-2, the wash supernatant is removed via magnetic separation. All of the photo-cleaved eluate is pipetted onto the MyOne magnetic beads and incubated with shaking at 25° C. for five minutes. The supernatant is removed from the MyOne beads via magnetic separation and 75 μL of SB17T is transferred to each well. The plate is mixed for one minute at 37° C. with shaking and then 75 μL of 60% glycerol (in SB17T) at 37° C. is transferred to each well. The plate is mixed for another minute at 37° C. with shaking. The wash is removed via magnetic separation. These washes are repeated two more times. After removal of the third glycerol wash from the MyOne beads, 150 μL of SB17T is added to each well and the plates incubated at 37° C. with shaking for one minute before removal by magnetic separation. The MyOne beads are washed a final time using 150 μL SB19T with incubation for one minute, prior to magnetic separation.

Catch-2 Bead Elution and Neutralization.

SOMAmers are eluted from MyOne beads by incubating each well of beads with 105 μL of 100 mM CAPSO pH 10, 1 M NaCl, 0.05% Tween with shaking for five minutes. 90 μL of each eluate is transferred during magnetic separation to a new 96-well plate containing 10 μL of 500 mM HCl, 500 mM HEPES, 0.05% Tween-20, pH 7.5.

Hybridization. 20 μL of each neutralized Catch-2 eluate is transferred to a new 96-well plate and 5 μL of 10× Agilent Block (Oligo aCGH/ChIP-on-chip Hybridization Kit, Large Volume, Agilent Technologies 5188-5380), containing a 10× spike of hybridization controls (10 Cy3 SOMAmers) is added to each well. After removing the plate from the robot, 25 μL of 2× Agilent Hybridization buffer (Oligo aCGH/ChIP-on-chip Hybridization Kit, Agilent Technologies) is manually pipetted to the each well of the plate containing the neutralized samples and blocking buffer. 40 μL of this solution is manually pipetted into each “well” of the hybridization gasket slide (Hybridization Gasket Slide—8 microarrays per slide format, Agilent Technologies). Custom Agilent microarray slides containing 10 probes per array complementary to 40 nucleotide selected region of each SOMAmer with a 20×dT linker are placed onto the gasket slides according to the manufacturer's protocol. Each assembly (Hybridization Chamber Kit-SureHyb enabled, Agilent Technologies) is tightly clamped and loaded into a hybridization oven for 19 hours at 60° C. rotating at 20 rpm. Post-Hybridization Washing. Approximately 400 mL Wash Buffer 1 (Oligo aCGH/ChIP-on-chip Wash Buffer 1, Agilent Technologies) is placed into each of two separate glass staining dishes. Six of the twelve slide/gasket assemblies are sequentially disassembled into the first staining dish containing Wash Buffer 1.

Once disassembled, the slide is quickly transferred into a slide rack in a second staining dish containing Wash Buffer 1. The slides are incubated for five minutes in Wash Buffer 1 with mixing via magnetic stir bar. The slide rack is then transferred to the 37° C. Wash Buffer 2 (Oligo aCGH/ChIP-onchip Wash Buffer 2, Agilent Technologies) and allowed to incubate for five minutes with stirring. The slide rack is transferred to a fourth staining dish containing acetonitrile and incubated for five minutes with stirring.

Microarray Imaging. The microarray slides are imaged with a microarray scanner (Agilent G2565CA Microarray Scanner System, Agilent Technologies) in the Cy3-channel at 5 μm resolution at 100% PMT setting and the XRD option enabled at 0.05. The resulting tiff images are processed using Agilent feature extraction software version 10.5.1.1 with the GE1_105_Dec08 protocol. 

1-28. (canceled) 29: A method of treating a bone metastasis disease in a subject, wherein said subject is characterized by: a) a high level of one or more proteins in at least one body fluid of said subject, wherein said one or more proteins are selected from the group consisting of: ICAM3 (UniProt ID: P32942); and/or b) a low level of one or more proteins in at least one body fluid of said subject, wherein said one or more proteins are selected from the group consisting of: MAP2K2 (UniProt ID: P36507), and MAPK11 (UniProt ID: Q15759); said method comprising: administering to said subject at least one pan αv integrin inhibitor, wherein said at least one pan αv integrin inhibitor comprises Abituzumab and/or Intetumumab; wherein a level of a specific protein of said one or more proteins in at least one body fluid of said subject is a) classified as high, if the level of the specific protein of said one or more proteins in said body fluid is at least 2% higher than a median threshold determined for the specific protein, and/or b) classified as low, if the level of the specific protein of said one or more proteins in said body fluid is at least 2% lower than said median threshold for the specific protein; and wherein a threshold or median threshold for the specific protein is determined from the body fluid of a plurality of subjects being part of a diseased subject population suffering from the bone metastasis disease. 30: The method according to claim 29, wherein said at least one pan αv integrin inhibitor comprises Abituzumab or consists of Abituzumab. 31: The method according to claim 29, wherein said at least one pan αv integrin inhibitor comprises Intetumumab or consists of Intetumumab. 32: The method according to claim 29, wherein said subject is additionally characterized by a high level of the protein STX1A (UniProt ID: Q16623); and/or a protein having at least 80% sequence homology to said protein. 33: The method according to claim 29, wherein said subject is characterized by the respective levels of one or more proteins having at least 80% sequence homology to said one or more proteins. 34: The method according to claim 29, wherein said body fluid is selected from the group consisting of blood plasma, blood serum, and whole blood. 35: The method according to claim 29, wherein said high levels and/or low levels of one or more of said proteins are present and/or determined prior to administering said at least one pan αv integrin inhibitor. 36: The method according to claim 29, wherein said high levels and/or low levels of one or more of said proteins are present and/or determined during or after administering said at least one pan αv integrin inhibitor. 37: The method according to claim 29, wherein the bone metastasis disease is cancer or is derived from cancer. 38: The method according to claim 29, wherein the bone metastasis disease is derived from prostate cancer, breast cancer and/or lung cancer. 39: The method according to claim 29, wherein said at least one pan αv integrin inhibitor is administered to said subject in an amount of 100 mg to 3000 mg per month. 40: The method according to claim 29, wherein said at least one pan αv integrin inhibitor comprises or is Abituzumab, and wherein the Abituzumab is administered to said subject in an amount of 500 to 2000 mg every week, every second week or every fourth week. 41: The method according to claim 29, wherein said at least one pan αv integrin inhibitor comprises or is Abituzumab, and wherein the Abituzumab is administered to said subject in an amount of about 500 mg per week, about 750 mg per week, about 1000 mg per week or about 1500 mg per week. 42: The method according to claim 29, wherein said at least one pan αv integrin inhibitor is administered in combination with one or more agents or chemotherapeutic agents, a) selected from the group consisting of Leuproreline, Leuproreline acetate, bicalutamide, nilutamide, triptoreline, gosereline, flutamide, cyproterone, busereline and degarelix, b) selected from the group consisting of Zoledronic acid, Pamidronic acid, Clodronate disodium, Alendronic acid and Ibandronic acid, and/or c) selected from the group consisting of Abiraterone, Abiraterone acetate, Prednisone, Enzalutamide, Radium Ra 223 dichloride, Docetaxel, Sipuleucel-T, Cabazitaxel and Mitoxantrone; and/or the pharmaceutically acceptable derivatives and/or salts thereof. 43: The method according to claim 29, wherein said at least one pan αv integrin inhibitor is administered in combination with, or additionally in combination with, one or more chemotherapeutic agents, selected from the group consisting of cetuximab, Panitumumab, irinotecan, vinorelbine, capecitabine, leucovorine, oxaliplatin, cisplatin, carboplatin, 5-fluorouracil (5-FU), bevacizumab, aflibercept and regorafenib. 44: The method according to claim 29, wherein said at least one pan αv integrin inhibitor is administered in combination with one or more agents or chemotherapeutic agents, selected from the group consisting of a) Leuproreline, Leuproreline acetate, bicalutamid, nilutamide, triptoreline, gosereline, flutamide, cyproterone, busereline and degarelix, and/or the pharmaceutically acceptable derivatives and/or salts thereof; and/or b) Zoledronic acid, Pamidronic acid, Clodronate disodium, Alendronic acid and Ibandronic acid, and/or the pharmaceutically acceptable derivatives and/or salts thereof. 